Comparative Analysis of Serum Proteomes of Moyamoya Disease and Normal Controls
Journal of Korean Neurosurgical Society
; : 8-13, 2010.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-114545
Responsible library:
WPRO
ABSTRACT
OBJECTIVE:
The etiology and pathogenesis of moyamoya disease remain unclear. Furthermore, the definitive diagnostic protein-biomarkers for moyamoya disease are still unknown. The present study analyzed serum proteomes from normal controls and moyamoya patients to identify novel serological biomarkers for diagnosing moyamoya disease.METHODS:
We compared the two-dimensional electrophoresis patterns of sera from moyamoya disease patients and normal controls and identified the differentially-expressed spots by matrix-assisted laser desorption/ionization-time-of flight mass spectrometry and electrospray ionization quadruple time-of-flight mass spectrometry.RESULTS:
We found and analyzed 22 differently-expressed proteomes. Two proteins were up-regulated. Twenty proteins were down-regulated. Complement C1 inhibitor protein and apolipoprotein C-III showed predominantly changed expressions (complement C1 inhibitor protein averaged a 7.23-fold expression in moyamoya patients as compared to controls, while apolipoprotein C-III averaged a 0.066-fold expression).CONCLUSION:
Although our study had a small sample size, our proteomic data provide serologic clue proteins for understanding moyamoya disease.
Full text:
Available
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
Health problem:
Goal 9: Noncommunicable diseases and mental health
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
Database:
WPRIM (Western Pacific)
Main subject:
Mass Spectrometry
/
Biomarkers
/
Proteins
/
Sample Size
/
Proteome
/
Electrophoresis
/
Complement C1 Inhibitor Protein
/
Apolipoprotein C-III
/
Moyamoya Disease
Limits:
Humans
Language:
English
Journal:
Journal of Korean Neurosurgical Society
Year:
2010
Document type:
Article